A new research study presented at the Alzheimer’s Association International Conference revealed that the use of the antibody solanezumab reduces the number of amyloid protein clumps (plaques) in the brain using human trials. What is the Breakthrough Study with Solanezumab? Eli Lilly (acclaimed pharmaceutical company) has found that solanezumab reduces the plaques that form in […]
Read More… from Study Reveals Solanezumab Slows Alzheimer’s Disease